Europe Anti-Obesity Drugs Market Strategies, Top Players, Growth Opportunities, Analysis and Forecast by 2031

Europe Anti-Obesity Drugs Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Prescription Drugs and OTC Drugs), Mechanism of Action (Centrally Acting Drugs, Peripherally Acting Drugs, and Others), Drug Class (GLP-1 Agonist, Lipase Inhibitors, MC4R agonist, and Others), GLP-1 Agonist [Semaglutide, Liraglutide, and Tirzepatide (Zepbound)], Application (Appetite Suppression, Inhibition of Fat Absorption or Digestive Enzymes, Metabolic Enhancement, and Combination), Route of Administration (Oral and Parenteral), and Distribution Channel (Hospital Pharmacies, Online Channel, and Retail Pharmacies)

  • Status : Published
  • Report Code : TIPRE00041493
  • Category : Life Sciences
  • No. of Pages : 234
  • Available Report Formats : pdf-format excel-format

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:

3.2.2 Macroeconomic factor analysis:

3.2.3 Developing base number:

3.2.4 Data Triangulation:

3.2.5 Country-level data:

4. Anti-Obesity Drugs Market Landscape

4.1 Market Overview

4.2 PEST Analysis

5. Europe Anti-Obesity Drugs Market - Key Market Dynamics

5.1 Market Drivers

5.2 Market Restraints

5.3 Market Opportunities

5.4 Future Trends

5.5 Impact of Drivers and Restraints:

6. Anti-Obesity Drugs Market - Europe Market Analysis

6.1 Europe Anti-Obesity Drugs Market Revenue (US$ Million), 2024 - 2031

6.2 Europe Anti-Obesity Drugs Market Forecast and Analysis

7. Europe Anti-Obesity Drugs Market Revenue Analysis - by Type

7.1 Prescription Drugs

7.1.1 Overview

7.1.2 Prescription Drugs: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

7.2 OTC Drugs

7.2.1 Overview

7.2.2 OTC Drugs: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

8. Europe Anti-Obesity Drugs Market Revenue Analysis - by Mechanism Of Action

8.1 Centrally Acting Drugs

8.1.1 Overview

8.1.2 Centrally Acting Drugs: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

8.2 Peripherally Acting Drugs

8.2.1 Overview

8.2.2 Peripherally Acting Drugs: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

8.3 Others

8.3.1 Overview

8.3.2 Others: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

9. Europe Anti-Obesity Drugs Market Revenue Analysis - by Drug Class

9.1 GLP-1 Agonist

9.1.1 Overview

9.1.2 GLP-1 Agonist: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

9.2 Lipase Inhibitors

9.2.1 Overview

9.2.2 Lipase Inhibitors: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

9.3 MC4R agonist

9.3.1 Overview

9.3.2 MC4R agonist: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

9.4 Others

9.4.1 Overview

9.4.2 Others: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

10. Europe Anti-Obesity Drugs Market Revenue Analysis - by Glp-1 Agonist

10.1 Semaglutide

10.1.1 Overview

10.1.2 Semaglutide: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

10.2 Liraglutide

10.2.1 Overview

10.2.2 Liraglutide: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

10.3 Tirzepatide (Zepbound)

10.3.1 Overview

10.3.2 Tirzepatide (Zepbound): Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

11. Europe Anti-Obesity Drugs Market Revenue Analysis - by Application

11.1 Appetite Suppression

11.1.1 Overview

11.1.2 Appetite Suppression: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

11.2 Inhibition of Fat Absorption or Digestive Enzymes

11.2.1 Overview

11.2.2 Inhibition of Fat Absorption or Digestive Enzymes: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

11.3 Metabolic Enhancement

11.3.1 Overview

11.3.2 Metabolic Enhancement: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

11.4 Combination

11.4.1 Overview

11.4.2 Combination: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

12. Europe Anti-Obesity Drugs Market Revenue Analysis - by Route Of Administration

12.1 Oral

12.1.1 Overview

12.1.2 Oral: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

12.2 Parenteral

12.2.1 Overview

12.2.2 Parenteral: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

13. Europe Anti-Obesity Drugs Market Revenue Analysis - by Distribution Channel

13.1 Hospital Pharmacies

13.1.1 Overview

13.1.2 Hospital Pharmacies: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

13.2 Online Channel

13.2.1 Overview

13.2.2 Online Channel: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

13.3 Retail Pharmacies

13.3.1 Overview

13.3.2 Retail Pharmacies: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

14. Europe Anti-Obesity Drugs Market - Country Analysis

14.1 Europe

14.1.1 Europe Anti-Obesity Drugs Market Revenue and Forecast and Analysis - by Country

14.1.1.1 Europe Anti-Obesity Drugs Market Revenue and Forecast and Analysis - by Country

14.1.2.2 Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

14.1.2.2.1 Germany: Europe Anti-Obesity Drugs Market Share - by Type

14.1.2.2.2 Germany: Europe Anti-Obesity Drugs Market Share - by Mechanism Of Action

14.1.2.2.3 Germany: Europe Anti-Obesity Drugs Market Share - by Drug Class

14.1.2.2.4 Germany: Europe Anti-Obesity Drugs Market Share - by Glp-1 Agonist

14.1.2.2.5 Germany: Europe Anti-Obesity Drugs Market Share - by Application

14.1.2.2.6 Germany: Europe Anti-Obesity Drugs Market Share - by Route Of Administration

14.1.2.2.7 Germany: Europe Anti-Obesity Drugs Market Share - by Distribution Channel

14.2.3.3 United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

14.2.3.3.1 United Kingdom: Europe Anti-Obesity Drugs Market Share - by Type

14.2.3.3.2 United Kingdom: Europe Anti-Obesity Drugs Market Share - by Mechanism Of Action

14.2.3.3.3 United Kingdom: Europe Anti-Obesity Drugs Market Share - by Drug Class

14.2.3.3.4 United Kingdom: Europe Anti-Obesity Drugs Market Share - by Glp-1 Agonist

14.2.3.3.5 United Kingdom: Europe Anti-Obesity Drugs Market Share - by Application

14.2.3.3.6 United Kingdom: Europe Anti-Obesity Drugs Market Share - by Route Of Administration

14.2.3.3.7 United Kingdom: Europe Anti-Obesity Drugs Market Share - by Distribution Channel

14.3.4.4 France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

14.3.4.4.1 France: Europe Anti-Obesity Drugs Market Share - by Type

14.3.4.4.2 France: Europe Anti-Obesity Drugs Market Share - by Mechanism Of Action

14.3.4.4.3 France: Europe Anti-Obesity Drugs Market Share - by Drug Class

14.3.4.4.4 France: Europe Anti-Obesity Drugs Market Share - by Glp-1 Agonist

14.3.4.4.5 France: Europe Anti-Obesity Drugs Market Share - by Application

14.3.4.4.6 France: Europe Anti-Obesity Drugs Market Share - by Route Of Administration

14.3.4.4.7 France: Europe Anti-Obesity Drugs Market Share - by Distribution Channel

14.4.5.5 Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

14.4.5.5.1 Spain: Europe Anti-Obesity Drugs Market Share - by Type

14.4.5.5.2 Spain: Europe Anti-Obesity Drugs Market Share - by Mechanism Of Action

14.4.5.5.3 Spain: Europe Anti-Obesity Drugs Market Share - by Drug Class

14.4.5.5.4 Spain: Europe Anti-Obesity Drugs Market Share - by Glp-1 Agonist

14.4.5.5.5 Spain: Europe Anti-Obesity Drugs Market Share - by Application

14.4.5.5.6 Spain: Europe Anti-Obesity Drugs Market Share - by Route Of Administration

14.4.5.5.7 Spain: Europe Anti-Obesity Drugs Market Share - by Distribution Channel

14.5.6.6 Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

14.5.6.6.1 Italy: Europe Anti-Obesity Drugs Market Share - by Type

14.5.6.6.2 Italy: Europe Anti-Obesity Drugs Market Share - by Mechanism Of Action

14.5.6.6.3 Italy: Europe Anti-Obesity Drugs Market Share - by Drug Class

14.5.6.6.4 Italy: Europe Anti-Obesity Drugs Market Share - by Glp-1 Agonist

14.5.6.6.5 Italy: Europe Anti-Obesity Drugs Market Share - by Application

14.5.6.6.6 Italy: Europe Anti-Obesity Drugs Market Share - by Route Of Administration

14.5.6.6.7 Italy: Europe Anti-Obesity Drugs Market Share - by Distribution Channel

14.6.7.7 Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

14.6.7.7.1 Rest of Europe: Europe Anti-Obesity Drugs Market Share - by Type

14.6.7.7.2 Rest of Europe: Europe Anti-Obesity Drugs Market Share - by Mechanism Of Action

14.6.7.7.3 Rest of Europe: Europe Anti-Obesity Drugs Market Share - by Drug Class

14.6.7.7.4 Rest of Europe: Europe Anti-Obesity Drugs Market Share - by Glp-1 Agonist

14.6.7.7.5 Rest of Europe: Europe Anti-Obesity Drugs Market Share - by Application

14.6.7.7.6 Rest of Europe: Europe Anti-Obesity Drugs Market Share - by Route Of Administration

14.6.7.7.7 Rest of Europe: Europe Anti-Obesity Drugs Market Share - by Distribution Channel

15 Competitive Landscape

15.1 Heat Map Analysis by Key Players

15.2 Company Positioning & Concentration

16 Industry Landscape

16.1 Overview

16.2 New Product Development

16.3 Merger and Acquisition

16.4 Other Strategic Developments

17 COMPANY PROFILES

17.1 GSK Plc

17.1.1 Key Facts

17.1.2 Business Description

17.1.3 Products and Services

17.1.4 Financial Overview

17.1.5 SWOT Analysis

17.1.6 Key Developments

17.2 F. Hoffmann-La Roche Ltd

17.2.1 Key Facts

17.2.2 Business Description

17.2.3 Products and Services

17.2.4 Financial Overview

17.2.5 SWOT Analysis

17.2.6 Key Developments

17.3 Teva Pharmaceutical Industries Ltd

17.3.1 Key Facts

17.3.2 Business Description

17.3.3 Products and Services

17.3.4 Financial Overview

17.3.5 SWOT Analysis

17.3.6 Key Developments

17.4 Novo Nordisk AS

17.4.1 Key Facts

17.4.2 Business Description

17.4.3 Products and Services

17.4.4 Financial Overview

17.4.5 SWOT Analysis

17.4.6 Key Developments

17.5 Eli Lilly and Co

17.5.1 Key Facts

17.5.2 Business Description

17.5.3 Products and Services

17.5.4 Financial Overview

17.5.5 SWOT Analysis

17.5.6 Key Developments

17.6 Sun Pharmaceutical Industries Ltd

17.6.1 Key Facts

17.6.2 Business Description

17.6.3 Products and Services

17.6.4 Financial Overview

17.6.5 SWOT Analysis

17.6.6 Key Developments

17.7 VIVUS LLC

17.7.1 Key Facts

17.7.2 Business Description

17.7.3 Products and Services

17.7.4 Financial Overview

17.7.5 SWOT Analysis

17.7.6 Key Developments

17.8 Currax Pharmaceuticals LLC.

17.8.1 Key Facts

17.8.2 Business Description

17.8.3 Products and Services

17.8.4 Financial Overview

17.8.5 SWOT Analysis

17.8.6 Key Developments

17.9 AdvaCare Pharma USA LLC

17.9.1 Key Facts

17.9.2 Business Description

17.9.3 Products and Services

17.9.4 Financial Overview

17.9.5 SWOT Analysis

17.9.6 Key Developments

17.10 Rhythm Pharmaceuticals Inc

17.10.1 Key Facts

17.10.2 Business Description

17.10.3 Products and Services

17.10.4 Financial Overview

17.10.5 SWOT Analysis

17.10.6 Key Developments

18. Appendix

18.1 About The Insight Partners

List of Tables

Table 1. Europe Anti-Obesity Drugs Market Segmentation

Table 2. List of Vendors

Table 3. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

Table 4. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type

Table 5. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action

Table 6. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class

Table 7. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by GLP-1 Agonist

Table 8. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application

Table 9. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration

Table 10. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel

Table 11. Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country

Table 12. Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type

Table 13. Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action

Table 14. Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class

Table 15. Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by GLP-1 Agonist

Table 16. Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application

Table 17. Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration

Table 18. Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel

Table 19. United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type

Table 20. United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action

Table 21. United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class

Table 22. United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by GLP-1 Agonist

Table 23. United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application

Table 24. United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration

Table 25. United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel

Table 26. France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type

Table 27. France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action

Table 28. France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class

Table 29. France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by GLP-1 Agonist

Table 30. France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application

Table 31. France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration

Table 32. France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel

Table 33. Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type

Table 34. Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action

Table 35. Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class

Table 36. Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by GLP-1 Agonist

Table 37. Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application

Table 38. Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration

Table 39. Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel

Table 40. Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type

Table 41. Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action

Table 42. Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class

Table 43. Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by GLP-1 Agonist

Table 44. Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application

Table 45. Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration

Table 46. Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel

Table 47. Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type

Table 48. Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action

Table 49. Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class

Table 50. Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by GLP-1 Agonist

Table 51. Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application

Table 52. Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration

Table 53. Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel

Table 54. Heat Map Analysis by Key Players

List of Figures

Figure 1. Europe Anti-Obesity Drugs Market Segmentation - Country

Figure 2. PEST Analysis

Figure 3. Ecosystem: Anti-Obesity Drugs Market

Figure 4. Europe Anti-Obesity Drugs Market - Key Market Dynamics

Figure 5. Impact Analysis of Drivers and Restraints

Figure 6. Europe Anti-Obesity Drugs Market Revenue (US$ Million), 2024 - 2031

Figure 7. Europe Anti-Obesity Drugs Market Share (%) - by Type, 2024 and 2031

Figure 8. Prescription Drugs: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

Figure 9. OTC Drugs: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

Figure 10. Europe Anti-Obesity Drugs Market Share (%) - by Mechanism Of Action, 2024 and 2031

Figure 11. Centrally Acting Drugs: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

Figure 12. Peripherally Acting Drugs: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

Figure 13. Others: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

Figure 14. Europe Anti-Obesity Drugs Market Share (%) - by Drug Class, 2024 and 2031

Figure 15. GLP-1 Agonist: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

Figure 16. Lipase Inhibitors: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

Figure 17. MC4R agonist: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

Figure 18. Others: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

Figure 19. Europe Anti-Obesity Drugs Market Share (%) - by GLP-1 Agonist, 2024 and 2031

Figure 20. Semaglutide: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

Figure 21. Liraglutide: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

Figure 22. Tirzepatide (Zepbound): Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

Figure 23. Europe Anti-Obesity Drugs Market Share (%) - by Application, 2024 and 2031

Figure 24. Appetite Suppression: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

Figure 25. Inhibition of Fat Absorption or Digestive Enzymes: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

Figure 26. Metabolic Enhancement: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

Figure 27. Combination: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

Figure 28. Europe Anti-Obesity Drugs Market Share (%) - by Route Of Administration, 2024 and 2031

Figure 29. Oral: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

Figure 30. Parenteral: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

Figure 31. Europe Anti-Obesity Drugs Market Share (%) - by Distribution Channel, 2024 and 2031

Figure 32. Hospital Pharmacies: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

Figure 33. Online Channel: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

Figure 34. Retail Pharmacies: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

Figure 35. Europe Anti-Obesity Drugs Market Breakdown by Key Countries, 2024 and 2031 (%)

Figure 36. Germany: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

Figure 37. United Kingdom: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

Figure 38. France: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

Figure 39. Spain: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

Figure 40. Italy: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

Figure 41. Rest of Europe: Europe Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

Figure 42. Company Positioning & Concentration

Your Key Concerns Addressed - Question & Answer
Can I view a sample of the report before purchasing?

Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.

Is analyst support included with the purchase?

Absolutely - analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.

What are the next steps once I place an order?

Once your order is successfully placed, you will receive a confirmation email along with your invoice.

• For published reports: You'll receive access to the report within 4-6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.

Can the report be tailored to suit my specific needs?

We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we'll be happy to provide a customized proposal or scope.

In what format is the report delivered?

The report is available in either PDF format or as an Excel dataset, depending on the license you choose.

The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.

How secure is the payment process on your platform?

Our payment process is fully secure and PCI-DSS compliant.

We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.

Do you provide special pricing for buying multiple reports?

Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we're happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you're considering, and we'll share a personalized quote.

Can I connect with your team to discuss the report before buying?

Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report's scope, methodology, customization options, or which license suits you best, we're here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.

Will I get a billing invoice upon purchase?

Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we'll be happy to assist.

Is there support available if I can't access my report?

Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we'll ensure the issue is resolved quickly so you can access your report without interruption.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Please use your business email for quicker response
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.